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Abstract 
Background: Recurrent pregnancy loss (RPL) is a multifactorial disorder. 
Environmental factors and genetics can affect pregnancy outcomes. 
Objective: Conflicting data suggest an association between estrogen receptor alpha 
(ESR1) gene polymorphisms and RPL. In this study, such association was 
investigated in Iranian women with RPL.  
Materials and Methods: In this case control study, blood samples were collected 
from 244 women with a history of three or more consecutive pregnancy losses and 
104 healthy women with at least two live births. Using polymerase chain reaction- 
restriction fragment length polymorphism (PCR-RFLP), we studied -397C/T and -
351A/G polymorphisms on ESR1 gene in case and control subjects. 
Results: The genotypic frequencies of -397C/T and -351A/G polymorphisms on 
ESR1were not significantly different between RPL and control groups (p=0.20 and 
p=0.09, respectively). A significantly negative correlation was observed between        
-397C/T and -351A/G (r=-0.852, p<0.001) in RPL women and complete linkage 
disequilibrium between the investigated polymorphisms was found (D’: 0.959; r-
square= 0.758, p<0.001). 
Conclusion: This investigation suggests that the analyzed polymorphisms on 
ESR1gene are not associated with an increased risk of RPL in the studied 
population. 
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Introduction 
 
ecurrent Pregnancy Loss (RPL) is 
defined as repeated occurrence of 3 
or more miscarriages before 20th 
week of gestation and its occurrence affects 
about 1-5% of couples (1, 2). Diverse factors 
have been claimed to cause of RPL, including; 
uterine anomalies, chromosomal 
abnormalities, endocrine and immune defects 
as well as thrombophilia and infection. In most 
cases, however, a single cause for repeated 
abortions cannot be identified (3). However, 
the development and function of female 
reproductive system are controlled by 
hypothalamus-pituitary-ovarian (HPO) axis. In 
addition, fertility and pregnancy may be 
negatively affected by the levels of hormones 
like follicle stimulating hormone (FSH), 
luteinizing hormone (LH), estradiol (E2) and 
progesterone that are also controlled by the 
HPO axis (4, 5). 
Estrogens modulate multiple reproductive 
functions, including progesterone production 
and uteroplacental blood flow (6). Factors like 
female secondary sexual characteristics, 
reproductive cycle, fertility, and maintenance 
of pregnancy may play a crucial role in 
embryonic and fetal development under the 
effect of estrogen (7, 8). Estrogen receptors 
(ERs), which in human consisted of ERα and 
ERβ, coded by ESR1 and ESR2 genes, 
respectively, are the mediator of estrogen 
signaling and function as ligand-dependent 
transcription factors (9, 10). ERsubtypes are 
members of nuclear hormone receptor 
R 
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superfamily. The ESR1 gene (140 kb) which is 
located on chromosome 6q25.1 consists of 8 
exons; likewise ESR2 gene is located on 
chromosome 14q22 and contains 8 exons. 
Both ESR1 and ESR2 genes are 
expressed in the human ovary, within the 
oocyte, in granulosa cells, in ovarian epithelial 
cells and in endometrial cells of uterine (11-
14). In recent years, increasing efforts have 
been made to describe genetic causes of 
recurrent miscarriage at the molecular level. 
Several polymorphic variants of the estrogen 
receptor genes have been described. More 
than 2200 single nucleotide polymorphisms 
(SNPs) have been identified in the ESR1 
gene, while this assessment for ESR2 gene is 
720 (www.snpper.chip.org). ESR1 and ESR2 
gene polymorphisms have been linked to a 
higher risk of unexplained infertility and to the 
outcome of controlled ovarian stimulation, as 
well as to the ovarian response to FSH (15, 
16). In the present study, we analyzed two 
SNPs (-397 C/T and -351 A/G) on the ESR1 
gene in Iranian women with RPL.  
Both these polymorphisms lie on intron 1 
and are recognized by PvuII (-397C/T) and 
XbaI (-351A/G) restriction enzymes and have 
been reported to be associated with RPL in 
Spanish and Taiwanese Han population (17, 
18). We therefore conducted a case-control 
study to examine the role of ESR1 SNPs and 
circulating concentrations of estradiol, FSH 
and LH with RPL risk. To our knowledge, 
there are no studies on the association of 
these polymorphisms and RPL in Iranian 
women. Also, in this study we compared 
Iranian haplotype with previous studies on 
different ethnic groups, to understand the 
analogy of different population. 
 
Materials and methods 
 
Patients 
In this case control study, the case group 
consisted of 244 women with at least three 
consecutive miscarriages before 20PthP week of 
gestation who referred to Avicenna Infertility 
Clinic, Tehran, Iran, between the years of 
2008-2010, for treatment of RPL. All patients 
had undergone standard diagnostic 
procedures, including a detailed history, 
chromosomal analyses of peripheral blood 
lymphocytes, ultrasonography and 
hysterosalpinogography to detect uterine 
anomalies, hormone profiles on day 2-3 of the 
menstrual cycles; FSH, LH, ER2R as well as 
thyroid hormone studies, investigation of 
infections and immunological diagnostics 
(including anti-phospholipid and anti-
cardiolipin antibodies). Women with uterine 
anomalies, karyotype abnormalities, 
hormonal, infection and immunological 
disorder were excluded from the study. 
The control group consisted of 104 healthy 
ethnically matched women with two or more 
successful pregnancies and live births and no 
history of complicated pregnancies, 
miscarriages, still births, small for gestational 
age fetuses, preeclampsia, ectopic pregnancy 
or preterm delivery. The study was approved 
by the Avicenna Research Institute local 
ethics committee for medical research, and 
written consents were obtained from 
participating subjects before entry into the 
study. 
 
Biochemical assays 
LH and FSH were measured by 
chemiluminescent immune assays (CLIA) 
(Diasorin, Italy). ER2R was measured by enzyme 
immunoassay (EIA) (Axis Shield, Dundee, 
UK). 
 
Isolation of genomic DNA 
Peripheral blood from each case and 
control subject was collected in vacutainer 
tubes containing ethylenediamine tetra acetic 
acid (EDTA) as anticoagulant followed by 
DNA extraction using salting out method (59T1959T). 
 
PCR-RFLP analysis of gene 
polymorphisms 
PCR-RFLP for the -397C/T and -351A/G 
polymorphisms were performed using specific 
primers and restriction enzymes (Table I). 
PCR reaction mixture contained 1 μg of total 
DNA, 1X Master Mix (Taq DNA Polymerase 
Master Mix Red, Ampliqon, Denmark) and 
10pM of each specific primer. The 
amplification cycles were 95 PoPC for 5 min, and 
35 cycles of 95PoPC for 30s, 60PoPC for 30s, and 
72PoPC for 30s, plus a final elongation at 72 PoPC 
for 5 min. The PCR products were then 
digested by restriction enzymes PvuII              
(-397C/T), XbaI (-351A/G) (Fermentas, 
Lithuania) (Table I) followed by running on a 
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Gel Red (Biotium, USA) stained 2-2.5% 
agarose gel. 
 
Statistical analysis 
Comparisons between groups for 
distribution of each polymorphism were made 
by Chi-square test. Student’s t- test was used 
to compare age, BMI and hormone levels 
between control and RPL groups. Correlations 
between different parameters were 
determined with Spearman's rank correlation 
test. Values of p<0.05 were regarded as 
significant. All statistical analyses were 
performed with SPSS version 13.0 (SPSS 
Inc., Chicago, IL). Haplotype analysis was 
determined with HaploView 4.2 (HaploView 
software Inc, USA). 
 
Results 
 
The average age of the case group was 
33.4 years (ranging from 20-48) and of the 
control group was 39.2 years (ranging from 
28-52). The genotype frequencies of all 
investigated polymorphisms in case and 
control groups are shown in table II. Allele 
frequency and genotype distributions of the 
ESR1 polymorphisms were not significantly 
different between the control and case groups 
(397C/T; p=0.20 and -351A/G; p=0.09). 
Heterozygous and homozygous polymorphic 
frequencies of -397C/T and -351A/G in the 
RPL group did not differ significantly from 
those in the controls.  
A significantly negative correlation was 
observed between the two ESR1 gene 
polymorphisms, -397C/T and -351A/G         
(r=-0.852, p<0.001) in RPL women. For this 
reason we conducted a study with inferred 
haplotypes (Figure 1 and Table III), (D’: 0.959; 
r-square= 0.758, p<0.001) as a consequence 
of the short distance between them. Table IV 
summarizes endocrine parameters for the 
cases and controls. We found no statistically 
significant differences between groups in 
levels of E2 and FSH. However, although 
women with increased the LH levels in the 
sera was excluded from the study, the level of 
LH (within the normal range) was significantly 
higher in RPL than that in controls (4.55±0.22 
vs. 3.04±0.28; p<0.001). In addition, genotype 
distribution analysis showed no correlation 
with the levels of E2, FSH and LH (data not 
shown). 
 
 
 
 
Table I. Primer sequences and restriction enzymes used to detect ER gene polymorphisms 
Polymorphism Primer sequences Amplicon size 
(bp) 
Restriction 
enzymes 
RFLP product size 
(bp) 
Allele 
ESR1 -397C/T F: 5′- GATATCC AGGGTTATGTGGCA-3′
¥ 
R:5′-AGGTGTTGCCTATTATATTAACCTTGA-3′ 346 PvuII 
346# C 
103 + 243† T 
ESR1 -351A/G   XbaI 148 + 198
# A 
 346† G 
ESR1; Estrogen receptor alpha gene,  #RFLP product for normal allele, 
†RFLP product for mutant allele.   ¥ The same primer set was used to amplify for both polymorphisms variants 
 
 
Table II. Genotype frequencies of RPL and control groups 
Polymorphism RPL n (%) Controls (n=104) n (%) p-value † 
-397C/T- ESR1 (n=241) 
 CC 41 (17.0) 10 (9.6)  
 TC 126 (52.3) 58 (55.8) 0.20 
 TT 74 (30.7) 36 (34.6)  
-351A/G - ESR1 (n=244) 
 AA 90 (36.9) 39 (37.5)  
 AG 121 (49.6) 59 (56.7) 0.09 
 GG 33 (13.5) 6 (5.8)  
† Determined by Chi- Square test. ESR1; estrogen receptor alpha gene  RPL; recurrent pregnancy loss 
 
 
Table III. Haplotype frequencies of -397C/T and -351A/G polymorphisms in control and RPL groups 
Haplotype Control RPL Control+ RPL 
Px (TA) 61.4% 55.9% 57.5% 
PX (CG) 33.3% 37.3% 36.2% 
Px (CA) 4.3% 6.0% 5.5% 
pX (TG) 1.0% 0.0% 0.0% 
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Table VI. Endocrine parameters in women with RPL and healthy controls 
Hormones Controls RPL p-value† 
E2 (pg/ml) 45.95 ± 5.90 37.44 ± 3.56 0.22 
FSH (IU/ml) 6.98 ± 0.41 7.50 ± 0.28 0.32 
LH (IU/ml) 3.03 ± 0.28 4.54 ± 0.22 <0.001 
†Determined by student’s t- test.  The data is presented as mean±SEM.  
 
 
 
 
Figure 1. Linkage disequilibrium comparisons of, -397C/T and -351A/G polymorphisms in settlement order in the ER1gene. 
 
Discussion 
 
Polymorphisms in the ERs influence 
vascular tone and flow and could result in a 
corresponding phenotypic difference in 
estrogen-dependent events, including those 
involved in pregnancy maintenance. Many 
studies have been performed to investigate 
the potential association between the -397T/C 
and -351A/G SNPs in ESR1 and recurrent 
miscarriage. In the present study, we found no 
significant differences in the allele distribution 
of the ESR1gene polymorphisms between 
RPL and healthy Iranian women. Our finding 
is in line with studies by Aléssio et al and 
Hanna et al who did not find any association 
between these two SNPs and RPL in Brazilian 
and Canadian population, respectively (5, 20). 
These findings may suggest that these two 
polymorphisms have little or no effect on 
maintenance of pregnancy. However, a recent 
study in Spain found an association between 
increased number of miscarriages and the 
ESR1 haplotype composed of the -397T and    
-351A alleles (17). 
These polymorphisms have opened an 
important area of research in reproductive 
disorders (RPL, infertility, endometriosis and 
age of menarche) and diseases such as 
osteoporosis, cardiovascular  and cancer (10, 
21-26). Conflicting results from different 
studies may be due to the differences in 
ascertainment of women with sporadic and 
recurrent miscarriage. Moreover, the 
combinatorial effects of SNPs, particularly in 
extremely polymorphic genes, and gene 
environmental interactions is difficult to 
appropriately address in association studies. 
There are some hypotheses in the literature 
which describe functional significance of these 
two ESR1 gene polymorphisms. They are 
located on, 397 and 351 bp upstream of the 
start of exon 2, and possible functional 
mechanisms include changes in ESR1 
expression due to altered binding of 
transcription factors and influence on 
alternative splicing of the ESR1 gene. These 
mechanisms can be caused directly by these 
polymorphisms or through linkage 
disequilibrium with a truly functional, but so far 
unknown sequence variation elsewhere in the 
ESR1 gene (27). 
Schuit et al reported that the -397T/C 
polymorphism is associated with decreased 
plasma E2 levels in an allele dose-dependent 
manner in postmenopausal women (27). They 
suggested that the potentially lower ESR1 
expression caused by the T-allele leads to a 
lower expression of an enzyme, such as 17β- 
Hydroxysteroiddehydrogenases (HSD), in the 
estrogen synthesis pathway and 
subsequently, reduced E2 synthesis. The fact 
that in the -351A/G polymorphism, the A-allele 
is also associated with E2 levels may be due 
to linkage disequilibrium with the -397T/C 
SNP or another functional polymorphism, or 
due to functional significance of the -351A/G 
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polymorphism itself (27). These findings 
suggest that the genotype-dependent 
differences in E2 levels created by these 
polymorphisms may be clinically significant. 
Similar to our study, Zofkova et al showed 
no association between ESR1 gene 
polymorphisms and sex hormone levels they 
found that the -397T/C and -351A/G 
polymorphisms were not significantly 
associated with E2 levels in a study of 114 
postmenopausal women. In the present study, 
the distribution of -397T/C and -351A/G 
polymorphisms (Table IV) was very similar to 
what was previously reported in Caucasian 
populations of European ancestry and differed 
significantly from what was observed in 
populations of Asiatic (28).  
Haplotype Px was detected, albeit in a low 
frequency whereas haplotype pX was not 
observed. This frequency of haplotypes may 
result from the disequilibrium which is not 
complete and may be due to recombination or 
multiple mutations which have occurred 
between/ at these two polymorphic sites. 
Endocrinological abnormalities are present in 
about a quarter of women with unexplained 
recurrent miscarriage (29). Several studies 
have reported high basal levels of LH, with or 
without polycystic ovaries, as a risk factor for 
miscarriage (30-32).  
In the present study we found that LH 
levels were significantly higher in RPL 
compared to controls. No significant 
differences were observed in the levels of 
FSH and E2 between the two groups which 
may be due to sample size. Larger studies 
may be needed to warrant a conclusion as to 
whether Iranian RPL women should be 
screened for the ESR1 gene polymorphisms.  
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